LLY.DE Earnings — Eli Lilly and Company
XETRA
Updated
When is LLY.DE's next earnings date?
Eli Lilly and Company (LLY.DE) has not announced its next earnings date yet. Its most recent earnings report was on Thursday, October 29, 2026.
How did LLY.DE do in its last earnings report?
In its most recent report on Oct 29, 2026, Eli Lilly and Company posted EPS of $6.60 versus the $5.02 estimate, a beat of 31.5%. Revenue was $21.54B against a $19.93B estimate.
How much does LLY.DE stock move after earnings?
LLY.DE beat EPS estimates in 2 of its last 2 reported quarters.
About Eli Lilly and Company
Eli Lilly and Company operates internationally as a pharmaceutical enterprise, dedicated to the discovery, development, and commercialization of human therapeutics. Its comprehensive product lineup addresses numerous critical health areas. Within the diabetes therapeutic area, Lilly provides a broad spectrum of insulin therapies, including the Basaglar, Humalog (with its various formulations like U-100, U-200, Mixes, and lispro variants), and Humulin (including 70/30, N, R, and U-500) families. Furthermore, for type 2 diabetes management, its offerings extend to Jardiance, Trajenta, and Trulicity. The company's oncology segment is robust, featuring treatments such as Alimta for non-small cell lung cancer and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for various colorectal and head and neck cancers; Retevmo for metastatic NSCLC and medullary/other thyroid cancers; Tyvyt for relapsed/refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio for specific types of metastatic and early breast cancer (HR+, HER2-). For autoimmune and inflammatory conditions, Lilly offers Olumiant to manage rheumatoid arthritis, and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. In the neuroscience domain, key products include Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Other significant therapies in its portfolio encompass Bamlanivimab and etesevimab, along with Bebtelovimab, developed to combat COVID-19; Cialis for addressing erectile dysfunction and benign prostatic hyperplasia; and Forteo for the treatment of osteoporosis. Eli Lilly maintains active strategic partnerships with a diverse group of organizations, including Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., AbCellera Biologics Inc., Junshi Biosciences, Regor Therapeutics Group, Lycia Therapeutics, Inc., Kumquat Biosciences Inc., Entos Pharmaceuticals Inc., and Foghorn Therapeutics Inc. Tracing its origins to 1876, Eli Lilly and Company is headquartered in Indianapolis, Indiana.
🤖 AI Earnings Analysis
Eli Lilly’s quarter was decisively strong, with $21.5B revenue beating by $1.6B and EPS of $6.60 topping estimates by $1.58. Extraordinary reported growth appears distorted, but the sizeable dual beat is compelling.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | 5.02 | 6.60 | +31.47% | $21.54B | ✅ Beat | — | — | — | |
| 2026-08-05 | 5.60 | 7.34 | — | $20.12B | ✅ Beat | — | — | — |
Showing last 2 quarters.
Revenue by segment & region
By segment
Q3 FY25 · $17.60B total
| Segment | Share | Revenue | YoY | Q3 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 |
|---|---|---|---|---|---|---|---|
| Cardiometabolic Health | 74.9% | $13.18B | +77.9% | — | — | $7.51B | $7.41B |
| Oncology | 13.7% | $2.41B | -5.8% | $1.75B | $2.08B | $2.46B | $2.56B |
| Immunology | 7.7% | $1.36B | +14.9% | $986.9M | $834.0M | $1.08B | $1.19B |
| Other Product, Total | 1.9% | $337.2M | +28.3% | $276.1M | $241.9M | $207.6M | $262.8M |
| Neuroscience | 1.8% | $315.7M | -32.7% | $1.77B | $552.5M | $487.0M | $469.0M |
By region
Q3 FY25 · $17.60B total
| Segment | Share | Revenue | YoY | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 64.2% | $11.30B | +44.6% | $5.69B | $7.84B | $7.81B | $9.03B |
| Europe | 19.9% | $3.50B | +114.8% | $1.44B | $1.40B | $1.63B | $2.45B |
| Non-US | 9.6% | $1.69B | +52.3% | $892.9M | $1.21B | $1.11B | — |
| CHINA | 3.2% | $560.4M | +21.9% | $376.2M | $395.1M | $459.9M | $429.2M |
| JAPAN | 3.2% | $554.7M | +29.3% | $363.9M | $462.7M | $429.1M | $559.2M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.